January 19, 2011

HLA-DQA1 * 02:01 Is a Major Risk Factor for Lapatinib-Induced Hepatotoxicity in Women With Advanced Breast Cancer

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

These results support a role for immune mechanisms in lapatinib-induced hepatotoxicity. Further work is required to determine whether testing for DQA1*02:01 allele carriage is clinically useful in managing liver safety risk during lapatinib treatment.

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Spraggs et al. (Wed,) studied this question.

synapsesocial.com/papers/69d94a919a6164e50fa3c799 https://doi.org/https://doi.org/10.1200/jco.2010.31.3197

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Differences in the risk of celiac disease associated with HLA-DQ2.5 or HLA-DQ2.2 are related to sustained gluten antigen presentation2009 · 148 citations
2TEACH: Tykerb Evaluation After Chemotherapy2007 · 28 citations
3Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer2006 · 3,465 citations
4Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1.1989 · 368 citations
5Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries1993 · 1,483 citations

Preguntar a la IA

Me gusta

Guardar